Video
Author(s):
Patients diagnosed with relapsing remitting multiple sclerosis have seen their treatment options increase dramatically in recent years. Now patients with the progressive forms are seeing the the start of momentum building in their favor.
Patients diagnosed with relapsing remitting multiple sclerosis have seen their treatment options increase dramatically in recent years. Now patients with the progressive forms are seeing the the start of momentum building in their favor.
Alan Thompson, MD, from University College London, and one of the leaders of the Progressive MS Alliance discussed the latest developments in treatment, including a trio of awards presented by the alliance at the annual ECTRIMS meeting in London. The awards, given to some of the leading minds in the field on international projects are meant to help keep the momentum moving forward and show demonstrable over the next four years and beyond.
Real-World Study Confirms Similar Efficacy of Guselkumab and IL-17i for PsA